{"meshTagsMajor":["Neoadjuvant Therapy"],"meshTags":["Time Factors","Neoadjuvant Therapy","Chemotherapy, Adjuvant","Humans","Genes, erbB-2","Breast Neoplasms","Antineoplastic Combined Chemotherapy Protocols","Neoplasm Metastasis"],"meshMinor":["Time Factors","Chemotherapy, Adjuvant","Humans","Genes, erbB-2","Breast Neoplasms","Antineoplastic Combined Chemotherapy Protocols","Neoplasm Metastasis"],"publicationTypes":["Evaluation Studies","Journal Article","Review"],"abstract":"In the last 20-30 years the approach to metastatic breast cancer by chemotherapy has been largely studied. Anthracyclines, taxanes and, more recently, capecitabine and gemcitabine represent the breakthrough of treatment. In the next future the combination of chemotherapy and target therapy will be considered more frequently.","title":"First line chemotherapy of metastatic breast cancer.","pubmedId":"16807448"}